Consensus Rani Therapeutics Holdings, Inc.

Stocks

RANI

US7530181004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-17 EDT			5-day change	1st Jan Change
0.6973 ^USD	+4.09%		+1.47%	-48.35%

07-15	Rani Therapeutics Reports Positive Initial Phase 1A Data for Rt-114 for the Treatment of Obesity	CI
07-15	Rani Therapeutics Reports Positive Initial Phase 1a Data for RT-114 in Obesity	MT

Evolution of the Average Target: Rani Therapeutics Holdings, Inc.

Evolution of the Target Price: Rani Therapeutics Holdings, Inc.

Changes in Analyst Recommendations: Rani Therapeutics Holdings, Inc.

9a1cfb445.KIfSwbpvmOsLlOGvt-NFPtoV5Y_C8L2gwRYOkhT8nkw.ZLCko8AY_pk9pJP10YY3cIVcvPmot97Qkl9N_WW-rRRY07CV1DqhnX2ltA~4c2d4dc076220de349a0972731a982b2

Analysts' recommendations: Rani Therapeutics Holdings, Inc.

25-10-20	Maxim Adjusts Rani Therapeutics Price Target to $10 From $5, Maintains Buy Rating	MT
25-10-17	Top Midday Gainers	MT
25-05-16	Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating	MT
24-08-02	Oppenheimer Initiates Rani Therapeutics Holdings at Outperform With $17 Price Target	MT
24-06-14	Maxim Starts Coverage on Rani Therapeutics With Buy Rating, $15 Price Target	MT
24-05-16	UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating	MT
24-05-07	HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating	MT
24-03-27	Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating	MT
24-03-25	HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating	MT
23-11-10	Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating	MT
23-11-09	HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Rani Therapeutics to $20 From $22, Keeps Buy Rating	MT
22-12-07	Wedbush Lifts Rani Therapeutics Holdings' Price Target to $20 From $19, Keeps Outperform Rating	MT
22-10-11	UBS Initiates Coverage on Rani Therapeutics With Buy Rating, $15 Price Target	MT
22-09-29	Wedbush Adjusts Rani Therapeutics Holdings Price Target to $19 From $17, Maintains Outperform Rating	MT
22-08-12	Wedbush Adjusts Price Target on Rani Therapeutics Holdings to $17 From $28, Keeps Outperform Rating	MT
22-07-27	HC Wainwright Initiates Rani Therapeutics Holdings at Buy With $22 Price Target	MT
22-06-13	Wedbush Starts Rani Therapeutics Holdings at Outperform With $28 Price Target	MT
21-08-25	RANI THERAPEUTICS : Canaccord Genuity Starts Rani Therapeutics Holdings at Buy With $29 Price Target	MT
21-08-25	RANI THERAPEUTICS : BTIG Starts Rani Therapeutics Holdings at Buy With $24 Price Target	MT
21-08-24	RANI THERAPEUTICS : Cantor Fitzgerald Starts Rani Therapeutics Holdings at Overweight with $23 Price Target	MT
21-08-24	RANI THERAPEUTICS : Stifel Starts Rani Therapeutics Holdings at Buy with $24 Price Target	MT
21-08-24	RANI THERAPEUTICS : BofA Securities Starts Rani Therapeutics Holdings at Buy with $23 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RANI THERAPEUTICS HOLDINGS, INC.					+975.58%
	ARGENX SE					+17.91%
	WUXI APPTEC CO., LTD.					+27.64%
	INSMED INCORPORATED					+81.3%
	BIONTECH SE					+33.1%
	WUXI BIOLOGICS (CAYMAN) INC.					+27.13%
	GENMAB A/S					+24.84%
	PHARMAESSENTIA CORPORATION					-10.18%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+14.72%
	EXELIXIS, INC.					-8.92%
	Average					+118.31%
	Weighted average by Cap.					+25.88%